Marcus S L, Dugan M H
Medical Research Division, Lederle Laboratories (a Division of American Cyanamid Co.), Pearl River, New York 10965.
Lasers Surg Med. 1992;12(3):318-24. doi: 10.1002/lsm.1900120313.
The clinical use of photodynamic therapy (PDT) has been ongoing for over a decade. However, attempts to apply for approval of the therapy from boards of health for general use began only in 1989. The unique nature of PDT and the resultant changes in the normal drug registration process, as well as steps which are being taken to approve PDT for the treatment of endobronchial lung cancer, superficial bladder cancer and esophageal cancer are described. The current clinical status of PDT in these indications is also reviewed.
光动力疗法(PDT)的临床应用已持续了十多年。然而,直到1989年才开始尝试向卫生委员会申请该疗法的通用批准。本文描述了PDT的独特性质以及正常药物注册过程中由此产生的变化,以及为批准PDT用于治疗支气管内肺癌、浅表性膀胱癌和食管癌所采取的步骤。还回顾了PDT在这些适应症方面的当前临床状况。